Supplementary Documents [IFRS]

Financial results for the the fiscal year 2019 (FY2019)

Astellas Pharma Inc.

- FY2019 Financial Results
  - For the year ended March 31, 2020
  - Three months ended March 31, 2020
- Pipeline list

Cautionary Notes
In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.
Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.

[For the year ended March 31, 2020]

1. Consolidated Results (Full Basis)

Unit: B¥

	FY18 Full Year	FY19 Full Year	Change	Change (%)	Revised Forecasts FY19 Full Year	Forecasts FY20 Full Year	Change from FY19 Change (%)
Revenue	1,306.3	1,300.8	-5.5	-0.4%	1,256.0	1,282.0	-1.4%
Cost of sales	292.0	276.7	-15.3	-5.2%			
Ratio to Revenue	22.4%	21.3%					
Gross profit	1,014.3	1,024.1	9.8	1.0%			
SG&A expenses	490.3	499.3	9.0	1.8%			
Ratio to Revenue	37.5%	38.4%					
Advertising and Sales Promotion	158.1	172.4	14.3	9.1%			
Personnel expenses	182.2	179.8	-2.3	-1.3%			
Other	150.0	147.0	-3.0	-2.0%			
R&D expenses	208.7	224.2	15.5	7.4%	216.0	239.0	6.6%
Ratio to Revenue	16.0%	17.2%			17.2%	18.6%	
Amortisation of intangible assets	35.2	21.2	-14.0	-39.9%			
Share of profit (loss) of investments accounted for using equity method	-1.6	-1.7	-0.0	-			
Other income	14.2	12.2	-2.0	-14.1%			
Gain on sales of property, plant and equipment	4.1	3.9	-0.2	-5.2%			
Gain from remeasurement relating to business combinations	5.8	-	-5.8	-			
Other expense	48.8	45.9	-2.8	-5.8%			
Impairment losses	11.4	13.8	2.3	20.5%			
Restructuring costs	19.3	1.8	-17.5	-90.5%			
Net foreign exchange losses	-	8.9	8.9	-			
Litigation costs	12.3	1.2	-11.1	-90.2%			
Fair value remeasurements on contingent consideration	3.8	11.2	7.4	193.7%			
Operating profit	243.9	244.0	0.1	0.0%	263.0	252.0	3.3%
Ratio to Revenue	18.7%	18.8%			20.9%	19.7%	
Finance income	6.4	4.4	-2.0	-31.4%			
Finance expense	1.3	3.0	1.7	130.7%			
Profit before tax	249.0	245.4	-3.6	-1.5%	263.0	251.0	2.3%
Ratio to Revenue	19.1%	18.9%			20.9%	19.6%	
Income tax expense	26.7	49.9	23.2	87.0%			
Profit	222.3	195.4	-26.9	-12.1%	210.0	202.0	3.4%
Ratio to Revenue	17.0%	15.0%			16.7%	15.8%	
Comprehensive income	222.2	156.7	-65.6	-29.5%			

2. Consolidated Results (Core Basis)

Unit: B¥

	FY18 Full Year	FY19 Full Year	Change	Change (%)	Revised Forecasts FY19 Full Year	Forecasts FY20 Full Year	Change from FY19 Change (%)
Revenue	1,306.3	1,300.8	-5.5	-0.4%	1,256.0	1,282.0	-1.4%
Cost of sales	292.0	276.7	-15.3	-5.2%			
Ratio to Revenue	22.4%	21.3%					
Gross profit	1,014.3	1,024.1	9.8	1.0%			
SG&A expenses	490.3	499.3	9.0	1.8%			
Ratio to Revenue	37.5%	38.4%					
Advertising and Sales Promotion	158.1	172.4	14.3	9.1%			
Personnel expenses	182.2	179.8	-2.3	-1.3%			
Other	150.0	147.0	-3.0	-2.0%			
R&D expenses	208.7	224.2	15.5	7.4%	216.0	239.0	6.6%
Ratio to Revenue	16.0%	17.2%			17.2%	18.6%	
Amortisation of intangible assets	35.2	21.2	-14.0	-39.9%			
Share of profit (loss) of investments accounted for using equity method	-1.6	-1.7	-0.0	-			
Operating profit	278.5	277.8	-0.8	-0.3%	264.0	257.0	-7.5%
Ratio to Revenue	21.3%	21.4%			21.0%	20.0%	
Finance income	6.3	4.4	-2.0	-31.2%			
Finance expense	1.3	3.0	1.7	130.7%			
Profit before tax	283.6	279.1	-4.4	-1.6%			
Ratio to Revenue	21.7%	21.5%					
Income tax expense	34.2	55.9	21.7	63.5%			
Profit	249.3	223.2	-26.2	-10.5%	214.0	206.0	-7.7%
Ratio to Revenue	19.1%	17.2%			17.0%	16.1%	

3. Exchange Rate

Unit: yen

	FY18 Ave.	FY19 Ave.	FY18 End	FY19 End	Revised Forecasts FY19 Full Year	Forecasts FY20 Full Year
USD/Yen	111	109	111	109	108	110
EUR/Yen	128	121	125	120	120	120

* Fx impacts:Net sales -36.7 billion yen and Core operating profit -12.6 billion yen

* Fx impact on elimination of unrealized gain: COGs ratio -0.3ppt

4. Reconciliation of Full Basis to Core Basis

Unit: B¥

	FY18 Full year			FY19 Full year		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Revenue	**1,306.3**	**-**	**1,306.3**	**1,300.8**	**-**	**1,300.8**
Cost of sales	292.0	-	292.0	276.7	-	276.7
Gross profit	**1,014.3**	**-**	**1,014.3**	**1,024.1**	**-**	**1,024.1**
SG&A expenses	490.3	-	490.3	499.3	-	499.3
R&D expenses	208.7	-	208.7	224.2	-	224.2
Amortisation of intangible assets	35.2	-	35.2	21.2	-	21.2
Share of profit (loss) of investments accounted for using equity method	-1.6	-	-1.6	-1.7	-	-1.7
Other income *	14.2	-14.2	-	12.2	-12.2	-
Other expense *	48.8	-48.8	-	45.9	-45.9	-
Operating profit	**243.9**	**34.6**	**278.5**	**244.0**	**33.8**	**277.8**
Finance income	6.4	-	6.3	4.4	-	4.4
Finance expense	1.3	-	1.3	3.0	-	3.0
Profit before tax	**249.0**	**34.6**	**283.6**	**245.4**	**33.8**	**279.1**
Income tax expense	26.7	7.5	34.2	49.9	6.0	55.9
Profit	**222.3**	**27.1**	**249.3**	**195.4**	**27.8**	**223.2**

* "Other income" and "Other expense" are excluded from Full basis results.
"Other income" and "Other expense" include gain/loss on sale and disposal of property, plant and equipment, impairment losses, restructuring costs, litigation costs and foreign exchange gains/losses, etc.

5. Revenue by Region

Unit: B¥

		FY18 Full Year	FY19 Full Year	Change	Change (%)	Revised Forecasts FY19 Full Year	Forecasts FY20 Full Year	Change from FY19 Change (%)
Revenue		1,306.3	1,300.8	-5.5	-0.4%	1,256.0	1,282.0	-1.4%
	Japan	369.5	345.4	-24.1	-6.5%	334.9	289.1	-16.3%
	Ratio to Revenue	28.3%	26.6%			26.7%	22.6%	
	United States	421.6	443.5	21.9	5.2%	427.8	490.9	10.7%
	Ratio to Revenue	32.3%	34.1%			34.1%	38.3%	
	Established Market	300.0	296.1	-3.9	-1.3%	283.8	299.0	1.0%
	Ratio to Revenue	23.0%	22.8%			22.6%	23.3%	
	Greater China	62.4	60.4	-2.1	-3.3%	62.5	67.6	12.0%
	Ratio to Revenue	4.8%	4.6%			5.0%	5.3%	
	International	122.7	134.8	12.1	9.9%	129.1	120.1	-10.9%
	Ratio to Revenue	9.4%	10.4%			10.3%	9.4%	
	Others	30.2	20.7	-9.5	-31.4%	18.0	15.3	-26.4%
	Ratio to Revenue	2.3%	1.6%			1.4%	1.2%	

- Established Market: Europe, Canada, Australia
- Greater China: China, Hong Kong, Taiwan
- International: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

6. Per Share Information

	FY18 Full Year	FY19 Full Year	Revised Forecasts FY19 Full Year	Forecasts FY20 Full Year
The number of shares issued (thousand)	1,979,823	1,861,787		
Treasury Shares (thousand)	93,986	4,276		
The number of shares issued after deducting Treasury Shares (thousand)	1,885,837	1,857,511		
Earnings per share (yen)	115.05	104.15	111.37	108.75
Earnings per share (yen) core base	129.07	118.95	113.49	110.90
Dividend per share (yen)	38	40	40	42
Return on Equity (%)	17.6%	15.3%		
Dividend on Earnings (%)	5.8%	5.9%		

7. Addition to Property, Plant and Equipment
Depreciation/Amortisation

Unit: B¥

		FY18 Full Year	FY19 Full Year	Change	Change (%)	Revised Forecasts FY19 Full Year	Forecasts FY20 Full Year	Change from FY19 Change (%)
Addition to Property, Plant and Equipment								
	Consolidated	27.7	41.8	14.0	50.5%	44.0	29.0	-30.6%
Depreciation (PP&E)								
	Consolidated	21.0	37.5	16.5	78.6%	35.0	41.0	9.3%
Amortisation (Intangible Assets (Including amortisation of software, etc.))								
	Consolidated	42.5	28.9	-13.6	-32.0%	27.5	30.0	3.9%

- Addition to Property, Plant and Equipment does not include right-of-use asset.

8. Sales of major products

1) Global

Unit: B¥

		FY18 Full Year	FY19 Full Year	Change	Change (%)	Revised Forecasts FY19 Full Year	Forecasts FY20 Full Year	Change from FY19 Change (%)
XTANDI		333.1	400.0	66.9	20.1%	383.9	459.3	14.8%
	United States	164.7	203.5	38.7	23.5%	195.0	238.3	17.1%
	ex-US	168.3	196.5	28.2	16.8%	189.0	221.0	12.5%
	Japan	32.3	35.8	3.5	10.7%	35.5	39.3	9.9%
	Established Market	119.0	135.4	16.5	13.8%	131.1	148.3	9.5%
	Greater China	2.2	3.2	1.0	47.1%	2.6	6.9	115.9%
	International	14.8	22.1	7.3	48.9%	19.8	26.5	19.9%
XOSPATA		2.5	14.3	11.7	467.6%	13.9	23.2	62.6%
	Japan	0.6	2.8	2.2	400.1%	2.5	3.2	14.8%
	United States	2.0	10.5	8.6	439.0%	11.1	13.8	30.9%
	Estabilished Market	-	0.9	0.9	-	0.3	5.6	498.5%
Betanis/Myrabetriq/BETMIGA		147.2	161.6	14.4	9.8%	158.8	172.5	6.8%
	Japan	32.7	34.3	1.6	5.0%	34.9	34.9	1.5%
	United States	80.8	89.2	8.5	10.5%	86.8	93.0	4.2%
	Estabilished Market	25.3	28.2	2.9	11.3%	27.1	31.4	11.4%
	Greater China	1.2	1.4	0.1	10.1%	1.4	3.1	125.7%
	International	7.2	8.4	1.3	17.8%	8.6	10.1	20.1%
Vesicare		95.0	44.7	-50.3	-52.9%	42.2	32.4	-27.5%
	Japan	22.3	20.2	-2.1	-9.3%	19.4	17.2	-14.8%
	United States	36.9	5.4	-31.4	-85.2%	3.8	3.1	-43.4%
	Estabilished Market	29.4	13.1	-16.3	-55.5%	13.1	6.5	-50.6%
	Greater China	1.9	1.8	-0.0	-1.4%	2.0	1.2	-34.4%
	International	4.6	4.2	-0.4	-8.7%	4.0	4.5	7.0%
Prograf		195.7	192.9	-2.8	-1.4%	190.3	186.3	-3.4%
	Japan	45.4	44.3	-1.1	-2.5%	42.7	41.1	-7.3%
	United States	14.0	13.2	-0.8	-5.8%	16.8	12.2	-7.6%
	Estabilished Market	74.4	71.5	-3.0	-4.0%	67.0	65.3	-8.7%
	Greater China	31.3	32.2	0.8	2.7%	32.4	35.4	9.8%
	International	30.5	31.7	1.2	4.0%	31.5	32.4	2.1%
Harnal/Omnic		47.4	42.7	-4.7	-10.0%	43.0	40.5	-5.2%
Funguard/MYCAMINE		34.5	35.2	0.7	2.0%	32.6	25.1	-28.7%
Eligard		14.8	14.2	-0.6	-4.0%	13.8	12.9	-9.2%

- Sales of products in Japan are shown in a gross sales basis
- EM(Established Market): Europe, Canada, Australia
- Greater China: China, Hong Kong, Taiwan
- International: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

2） Revenue by region

(1) Japan

Unit: B¥

<Global>	FY18 Full Year	FY19 Full Year	Change	Change (%)	Revised Forecasts FY19 Full Year	Forecasts FY20 Full Year	Change from FY19 Change (%)
XTANDI	32.3	35.8	3.5	10.7%	35.5	39.3	9.9%
XOSPATA	0.6	2.8	2.2	400.1%	2.5	3.2	14.8%
Betanis	32.7	34.3	1.6	5.0%	34.9	34.9	1.5%
Vesicare	22.3	20.2	-2.1	-9.3%	19.4	17.2	-14.8%
Prograf （Including Graceptor）	45.4	44.3	-1.1	-2.5%	42.7	41.1	-7.3%
Harnal	5.2	4.1	-1.0	-20.2%	3.9	2.6	-36.1%
Funguard	7.6	7.6	0.0	0.1%	6.7	3.6	-52.8%
<Main products>							
Suglat [Family]	17.8	23.9	6.1	34.1%	24.4	32.3	35.2%
Sujanu	4.4	8.9	4.5	102.7%			
Repatha	2.5	3.1	0.6	25.0%			
Linzess	3.9	5.6	1.6	41.5%	5.4	6.6	19.4%
BLINCYTO	1.1	4.5	3.3	294.7%			
EVENITY	0.6	23.6	23.0	-			
Celecox	49.4	49.2	-0.2	-0.5%	49.6	20.9	-57.4%
Symbicort	41.2	14.1	-27.0	-65.7%		-	-
Geninax	8.4	7.7	-0.7	-8.0%	8.2	7.1	-7.5%
Vaccines	29.8	11.2	-18.6	-62.4%	11.2	7.4	-34.0%
Gonax	4.8	5.1	0.4	7.5%	4.9	5.5	7.3%
Cimzia	9.4	9.3	-0.1	-1.4%	9.2	9.4	1.2%
Micardis [Family]	22.6	17.7	-4.9	-21.6%	17.2	-	-
Bonoteo	9.0	6.0	-3.0	-33.1%	5.9	3.2	-46.3%
Lipitor	15.2	12.7	-2.5	-16.3%	12.3	10.0	-21.3%
Myslee	10.7	9.0	-1.6	-15.4%	8.8	7.2	-20.8%
Total Rx Sales In Japanese market	366.2	342.1	-24.0	-6.6%	331.7	283.0	-17.3%

- Sales of products in Japan are shown in a gross sales basis.

(2) United States

Unit: M$

		FY18 Full Year	FY19 Full Year	Change	Change (%)	Revised Forecasts FY19 Full Year	Forecasts FY20 Full Year	Change from FY19 Change (%)
Revenue		3,801	4,078	277	7.3%	3,949	4,463	9.4%
	XTANDI	1,485	1,871	386	26.0%	1,800	2,166	15.8%
	XOSPATA	18	97	79	449.8%	102	125	29.4%
	PADCEV	-	17	17	-			
	Myrbetriq	728	821	92	12.7%	801	845	3.0%
	VESIcare	333	50	-283	-84.9%	35	28	-44.1%
	Prograf	127	122	-5	-3.9%	155	111	-8.7%
	MYCAMINE	97	106	10	9.9%	99	78	-27.1%
	AmBisome	110	116	6	5.8%	111	118	1.4%
	CRESEMBA	119	155	36	30.5%	143	167	7.7%
	Scan	690	694	4	0.6%	679	708	2.1%
	Tarceva	95	30	-65	-68.6%			

(3) Established Market

Unit: M€

		FY18 Full Year	FY19 Full Year	Change	Change (%)	Revised Forecasts FY19 Full Year	Forecasts FY20 Full Year	Change from FY19 Change (%)
Revenue		2,336	2,451	115	4.9%	2,370	2,492	1.7%
	XTANDI	926	1,121	195	21.0%	1,095	1,236	10.2%
	XOSPATA	-	8	8	-	3	47	498.5%
	BETMIGA	197	233	36	18.3%	226	262	12.1%
	Vesicare	229	108	-121	-52.7%	109	54	-50.2%
	Prograf	580	592	12	2.1%	559	544	-8.1%
	Omnic	71	71	1	1.0%	68	68	-4.5%
	MYCAMINE	60	56	-4	-6.5%	53	40	-28.3%
	Eligard	102	98	-4	-3.9%	94	85	-13.0%

- Established Market: Europe, Canada, Australia

(4) Greater China

Unit: B¥

	FY18 Full Year	FY19 Full Year	Change	Change (%)	Revised Forecasts FY19 Full Year	Forecasts FY20 Full Year	Change from FY19 Change (%)
Revenue	62.4	60.4	-2.1	-3.3%	62.5	67.6	12.0%
XTANDI	2.2	3.2	1.0	47.1%	2.6	6.9	115.9%
BETMIGA	1.2	1.4	0.1	10.1%	1.4	3.1	125.7%
Vesicare	1.9	1.8	-0.0	-1.4%	2.0	1.2	-34.4%
Prograf	31.3	32.2	0.8	2.7%	32.4	35.4	9.8%
Harnal	15.2	13.1	-2.1	-14.1%	14.7	11.4	-12.5%
MYCAMINE	3.6	3.8	0.2	6.2%	3.6	3.7	-1.9%
Eligard	0.3	0.3	0.1	22.3%	0.3	0.4	19.5%
Feburic	2.5	2.5	0.0	1.1%	3.0	4.0	56.5%

- Greater China: China, Hong Kong, Taiwan

(5) International

Unit: B¥

	FY18 Full Year	FY19 Full Year	Change	Change (%)	Revised Forecasts FY19 Full Year	Forecasts FY20 Full Year	Change from FY19 Change (%)
Revenue	122.7	134.8	12.1	9.9%	129.1	120.1	-10.9%
XTANDI	14.8	22.1	7.3	48.9%	19.8	26.5	19.9%
BETMIGA	7.2	8.4	1.3	17.8%	8.6	10.1	20.1%
Vesicare	4.6	4.2	-0.4	-8.7%	4.0	4.5	7.0%
Prograf	30.5	31.7	1.2	4.0%	31.5	32.4	2.1%
Harnal	18.0	16.9	-1.1	-6.1%	16.3	18.2	8.0%
MYCAMINE	4.9	5.5	0.6	11.2%	5.2	4.4	-19.1%

- International: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

9. Consolidated statements of financial position

Unit: B¥

	FY18 End	FY19 End	Change
Assets	**1,897.6**	**2,318.2**	**420.5**
Non-current assets	**1,040.5**	**1,450.6**	**410.2**
Property, plant and equipment	173.5	268.6	95.1
Goodwill	225.9	267.5	41.6
Intangible assets	429.7	738.5	308.8
Trade and other receivables	25.2	34.0	8.8
Investments accounted for using equity method	3.7	4.7	1.0
Deferred tax assets	93.0	52.9	-40.1
Other financial assets	81.5	74.3	-7.2
Other non-current assets	8.1	10.2	2.1
Current assets	**857.2**	**867.5**	**10.4**
Inventories	151.5	151.0	-0.5
Trade and other receivables	342.6	347.0	4.4
Income tax receivable	20.1	23.6	3.4
Other financial assets	2.6	9.5	6.9
Other current assets	25.1	18.0	-7.0
Cash and cash equivalents	311.1	318.4	7.3
Assets held for sale	4.1	-	-4.1

Unit: B¥

	FY18 End	FY19 End	Change
Equity and Liabilities	**1,897.6**	**2,318.2**	**420.5**
Equity	**1,258.4**	**1,289.2**	**30.8**
Equity attributable to owners of the parent	**1,258.4**	**1,289.2**	**30.8**
Share capital	103.0	103.0	-
Capital surplus	177.3	177.5	0.2
Treasury shares	-164.6	-7.2	157.5
Retained earnings	992.0	905.9	-86.1
Other components of equity	150.8	110.0	-40.8
Liabilities	**639.3**	**1,029.0**	**389.7**
Non-current liabilities	**141.6**	**230.3**	**88.7**
Trade and other payables	1.6	3.1	1.6
Deferred tax liabilities	5.2	27.7	22.5
Retirement benefit liabilities	40.2	38.1	-2.1
Provisions	5.4	6.1	0.7
Other financial liabilities	52.9	129.3	76.4
Other non-current liabilities	36.4	26.0	-10.4
Current liabilities	**497.7**	**798.7**	**301.0**
Trade and other payables	185.3	172.0	-13.3
Income tax payable	17.6	4.0	-13.6
Provisions	22.8	14.2	-8.6
Other financial liabilities	14.1	345.7	331.6
Other current liabilities	255.9	262.8	6.9
Liabilities directly associated with assets held for sale	1.9	-	-1.9

10. Employees

Number of employees

	FY18 End	FY19 End
Total	16,243	15,883

11. Shareholders

	FY18 End	FY19 End
Banks	32.4%	35.6%
Securities	4.3%	2.8%
Other companies	3.0%	3.2%
Foreign companies	47.0%	49.8%
Individuals and others	8.6%	8.6%
Treasury Stock*	4.7%	0.1%

* Treasury Stock does not include shares owned by the executive compensation BIP (Board Incentive Plan) trust.

[For the year ended March 31, 2020]

1. Consolidated Results (Full Basis)

Unit: B¥

	FY19							
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue	334.1	1.5%	316.3	-0.5%	338.1	-5.6%	312.3	3.6%
Cost of sales	70.5	-0.3%	68.4	-6.1%	82.8	-1.7%	55.1	-14.4%
Ratio to Revenue	21.1%		21.6%		24.5%		17.6%	
Gross profit	263.6	2.0%	248.0	1.1%	255.3	-6.7%	257.2	8.5%
SG&A expenses	117.5	4.1%	108.6	-8.5%	127.5	2.6%	145.7	8.4%
Ratio to Revenue	35.2%		34.3%		37.7%		46.7%	
Advertising and Sales Promotion	41.3	12.2%	40.3	9.3%	44.8	8.5%	46.0	6.8%
Personnel expenses	43.6	-1.8%	42.8	-4.6%	43.3	-2.7%	50.2	3.5%
Other	32.6	2.9%	25.5	-30.9%	39.4	2.4%	49.5	15.4%
R&D expenses	53.5	2.6%	51.5	8.5%	54.8	8.7%	64.5	9.8%
Ratio to Revenue	16.0%		16.3%		16.2%		20.6%	
Amortisation of intangible assets	7.2	-20.6%	4.0	-53.4%	4.2	-52.0%	5.7	-34.4%
Share of profit (loss) of investments accounted for using equity method	-0.7	-	-0.7	-	-0.8	-	0.5	-
Other income	4.5	6.7%	2.7	494.9%	7.8	-22.3%	2.4	-11.1%
Gain on sales of property, plant and equipment	-	-	-	-	3.9	-	-	-
Net foreign exchange gains	0.5	-	1.4	-	2.7	63.3%	-	-
Other expense	12.2	-50.8%	0.8	-88.7%	0.4	-97.9%	37.8	-
Impairment losses	-	-	0.1	-98.2%	-	-	13.7	-
Net foreign exchange losses	-	-	-	-	-	-	13.5	-
Fair value remeasurements on contingent consideration	11.4	-	0.5	-	0.1	-	-	-
Operating profit	77.1	21.3%	85.1	34.5%	75.5	-8.6%	6.3	-81.7%
Ratio to Revenue	23.1%		26.9%		22.3%		2.0%	
Finance income	0.8	-34.3%	0.6	-39.4%	2.5	10.9%	0.5	-73.4%
Finance expense	1.3	504.1%	0.6	45.0%	0.4	42.8%	0.7	73.3%
Profit before tax	76.5	18.7%	85.1	33.3%	77.6	-8.2%	6.2	-82.9%
Ratio to Revenue	22.9%		26.9%		23.0%		2.0%	
Income tax expense	18.0	81.3%	15.0	3.8%	16.1	-613.2%	0.8	-85.7%
Profit	58.5	7.3%	70.0	42.0%	61.5	-29.9%	5.4	-82.5%
Ratio to Revenue	17.5%		22.1%		18.2%		1.7%	
Comprehensive income	27.0	-61.8%	47.5	-40.1%	95.8	108.5%	-13.7	-

2. Consolidated Results (Core Basis)

Unit: B¥

	FY19							
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue	334.1	1.5%	316.3	-0.5%	338.1	-5.6%	312.3	3.6%
Cost of sales	70.5	-0.3%	68.4	-6.1%	82.8	-1.7%	55.1	-14.4%
Ratio to Revenue	21.1%		21.6%		24.5%		17.6%	
Gross profit	263.6	2.0%	248.0	1.1%	255.3	-6.7%	257.2	8.5%
SG&A expenses	117.5	4.1%	108.6	-8.5%	127.5	2.6%	145.7	8.4%
Ratio to Revenue	35.2%		34.3%		37.7%		46.7%	
Advertising and Sales Promotion	41.3	12.2%	40.3	9.3%	44.8	8.5%	46.0	6.8%
Personnel expenses	43.6	-1.8%	42.8	-4.6%	43.3	-2.7%	50.2	3.5%
Other	32.6	2.9%	25.5	-30.9%	39.4	2.4%	49.5	15.4%
R&D expenses	53.5	2.6%	51.5	8.5%	54.8	8.7%	64.5	9.8%
Ratio to Revenue	16.0%		16.3%		16.2%		20.6%	
Amortisation of intangible assets	7.2	-20.6%	4.0	-53.4%	4.2	-52.0%	5.7	-34.4%
Share of profit (loss) of investments accounted for using equity method	-0.7	-	-0.7	-	-0.8	-	0.5	-
Operating profit	84.7	0.8%	83.2	18.6%	68.0	-24.3%	41.8	21.1%
Ratio to Revenue	25.4%		26.3%		20.1%		13.4%	
Finance income	0.8	-34.2%	0.6	-39.4%	2.5	11.0%	0.5	-73.2%
Finance expense	1.3	504.1%	0.6	45.0%	0.4	42.8%	0.7	73.3%
Profit before Tax	84.2	-0.9%	83.2	17.7%	70.1	-23.6%	41.6	15.3%
Ratio to Revenue	25.2%		26.3%		20.7%		13.3%	
Income tax expense	17.1	16.7%	14.4	-11.5%	14.2	-	10.3	122.1%
Profit	67.1	-4.6%	68.8	26.4%	55.9	-39.9%	31.3	-0.4%
Ratio to Revenue	20.1%		21.7%		16.5%		10.0%	

3. Revenue by Region

Unit: B¥

		FY19							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue		334.1	1.5%	316.3	-0.5%	338.1	-5.6%	312.3	3.6%
	Japan	98.5	4.6%	84.9	-2.0%	92.8	-16.5%	69.2	-10.9%
	Ratio to Revenue	29.5%		26.8%		27.5%		22.2%	
	United States	105.3	2.5%	111.4	5.9%	115.1	1.7%	111.6	11.1%
	Ratio to Revenue	31.5%		35.2%		34.1%		35.7%	
	Established Market	75.8	-1.4%	71.0	-2.4%	71.2	-10.2%	78.1	10.0%
	Ratio to Revenue	22.7%		22.4%		21.1%		25.0%	
	Greater China	14.7	7.4%	14.7	-5.9%	14.9	-5.1%	16.0	-7.8%
	Ratio to Revenue	4.4%		4.6%		4.4%		5.1%	
	International	34.2	6.6%	29.1	-6.2%	39.5	25.6%	32.0	13.8%
	Ratio to Revenue	10.2%		9.2%		11.7%		10.2%	
	Others	5.6	-41.0%	5.3	-23.2%	4.4	-37.4%	5.4	-20.3%
	Ratio to Revenue	1.7%		1.7%		1.3%		1.7%	

- Established Market: Europe, Canada, Australia
- Greater China: China, Hong Kong, Taiwan
- International: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

4. Addition to Property,Plant and Equipment
Depreciation/Amortisation

Unit: B¥

		FY19							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Addition to Property, Plant and Equipment									
	Consolidated	12.6	103.6%	9.9	28.6%	9.4	55.0%	9.9	26.4%
Depreciation (PP&E)									
	Consolidated	8.0	53.5%	8.3	54.8%	11.1	110.9%	10.1	95.7%
Amortisation (Intangible Assets (Including amortisation of software, etc.))									
	Consolidated	9.0	-17.2%	5.9	-43.7%	6.0	-43.3%	8.0	-24.2%

- Addition to Property, Plant and Equipment does not include right-of-use asset.

5. Sales of major products

1) Global

Unit: B¥

	FY19							
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
XTANDI	96.0	18.2%	99.0	19.6%	102.9	15.1%	102.1	28.1%
United States	46.9	19.3%	51.8	23.1%	53.2	18.7%	51.6	33.9%
ex-US	49.1	17.3%	47.2	16.0%	49.7	11.4%	50.5	22.8%
Japan	9.3	9.2%	9.4	13.9%	9.1	9.1%	8.0	10.5%
Established Market	33.6	14.5%	32.5	12.5%	33.1	5.5%	36.3	23.5%
Greater China	0.5	24.1%	0.5	-7.0%	0.7	23.5%	1.5	128.6%
International	5.7	58.7%	4.8	58.3%	6.8	57.2%	4.8	23.0%
XOSPATA	2.5	-	3.3	-	4.0	-	4.5	137.4%
Japan	0.6	-	0.7	-	0.9	-	0.6	68.8%
United States	1.9	-	2.6	-	3.0	-	3.1	103.2%
Estabilished Market	-	-	-	-	0.2	-	0.8	-
PADCEV	-	-	-	-	0.0	-	1.8	-
United States	-	-	-	-	0.0	-	1.8	-
Betanis/Myrabetriq/BETMIGA	39.9	16.1%	38.9	13.6%	42.2	2.3%	40.5	8.7%
Japan	9.4	16.6%	8.5	13.2%	9.6	4.1%	6.9	-13.4%
United States	21.3	16.4%	21.2	13.0%	23.0	0.3%	23.8	14.3%
Estabilished Market	6.8	9.6%	6.9	13.4%	7.2	5.4%	7.3	17.5%
Greater China	0.4	52.0%	0.3	2.2%	0.3	-12.7%	0.4	7.5%
International	2.1	29.2%	2.0	25.5%	2.2	8.2%	2.1	11.6%
Vesicare	13.6	-45.6%	11.5	-50.4%	11.1	-57.8%	8.6	-58.4%
Japan	5.7	-5.3%	4.8	-7.2%	5.5	-9.9%	4.0	-16.0%
United States	0.2	-97.8%	2.5	-72.7%	1.8	-83.9%	0.9	-86.7%
Estabilished Market	6.1	-22.4%	2.6	-63.7%	2.2	-71.0%	2.2	-67.8%
Greater China	0.5	14.6%	0.5	0.7%	0.5	-1.6%	0.4	-16.4%
International	1.1	-6.6%	1.1	-7.6%	1.1	5.2%	0.9	-23.8%
Prograf	50.4	-3.4%	45.7	-5.0%	50.0	0.8%	46.7	2.2%
Japan	12.2	0.2%	10.7	-4.8%	12.0	-2.7%	9.4	-2.8%
United States	3.2	-15.9%	3.8	-2.8%	3.9	13.1%	2.3	-19.3%
Estabilished Market	17.7	-10.1%	16.7	-7.0%	17.2	-13.6%	19.9	17.7%
Greater China	7.7	13.2%	7.8	-1.8%	7.7	-1.4%	9.0	2.3%
International	9.6	-1.0%	6.8	-5.5%	9.2	50.1%	6.1	-18.1%
Harnal/Omnic	10.9	-4.7%	11.3	-6.2%	11.1	-11.0%	9.4	-18.1%
Funguard/MYCAMINE	9.0	3.2%	8.7	-7.6%	9.5	11.3%	7.9	1.9%
Eligard	3.6	-11.7%	3.2	-6.2%	3.8	-3.2%	3.5	7.1%

- Sales of products in Japan are shown in a gross sales basis
- Established Market: Europe, Canada, Australia
- Greater China: China, Hong Kong, Taiwan
- International: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

2）Revenue by region

(1) Japan

Unit: B¥

	FY19							
<Global>	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
XTANDI	9.3	9.2%	9.4	13.9%	9.1	9.1%	8.0	10.5%
XOSPATA	0.6	-	0.7	-	0.9	-	0.6	68.8%
Betanis	9.4	16.6%	8.5	13.2%	9.6	4.1%	6.9	-13.4%
Vesicare	5.7	-5.3%	4.8	-7.2%	5.5	-9.9%	4.0	-16.0%
Prograf （Including Graceptor ）	12.2	0.2%	10.7	-4.8%	12.0	-2.7%	9.4	-2.8%
Harnal	1.2	-17.2%	1.0	-19.8%	1.1	-21.7%	0.8	-23.0%
Funguard	2.0	9.5%	1.9	-25.4%	2.2	32.8%	1.4	-4.3%
<Main products>								
Suglat [Family]	6.0	22.2%	5.7	63.4%	6.7	34.1%	5.5	24.4%
Sujanu	2.1	43.9%	2.1	811.5%	2.6	96.7%	2.2	53.7%
Repatha	0.8	30.1%	0.7	21.4%	0.9	23.0%	0.8	26.0%
Linzess	1.4	76.4%	1.3	59.0%	1.6	27.7%	1.3	18.5%
BLINCYTO	1.0	-	1.1	-	1.3	-	1.0	32.8%
EVENITY	3.5	-	6.0	-	7.0	-	7.2	-
Celecox	13.1	2.2%	13.1	6.5%	12.6	-7.5%	10.3	-2.8%
Symbicort	11.0	4.0%	3.2	-64.2%	-	-	-	-
Geninax	2.2	5.4%	1.8	17.3%	2.3	-18.7%	1.4	-27.9%
Vaccines	3.3	2.9%	1.9	-64.2%	6.2	-66.6%	-0.1	-104.5%
Gonax	1.3	8.8%	1.3	9.2%	1.4	5.9%	1.1	5.9%
Cimzia	2.4	1.6%	2.3	-1.5%	2.5	-3.1%	2.0	-2.5%
Micardis [Family]	5.3	-21.2%	4.3	-20.9%	4.7	-21.9%	3.4	-22.8%
Bonoteo	1.8	-46.2%	1.5	-25.6%	1.6	-25.5%	1.1	-25.1%
Lipitor	3.7	-12.6%	3.2	-16.0%	3.3	-18.9%	2.5	-18.4%
Myslee	2.5	-11.9%	2.3	-15.9%	2.4	-16.9%	1.8	-17.5%
Total Rx Sales In Japanese market	97.9	5.3%	84.4	-1.6%	91.5	-16.9%	68.3	-11.6%

- Sales of products in Japan are shown in a gross sales basis.

(2) United States

Unit: M$

	FY19							
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue	958	1.7%	1,037	9.9%	1,059	5.5%	1,024	12.4%
XTANDI	427	18.4%	481	27.5%	489	23.2%	474	35.4%
XOSPATA	17	-	24	-	28	-	28	106.8%
PADCEV	-	-	-	-	0	-	17	-
Myrbetriq	194	15.5%	197	17.3%	211	3.9%	218	15.7%
Vesicare	2	-97.8%	23	-72.0%	16	-83.3%	9	-86.6%
Prograf	29	-16.6%	35	0.8%	36	17.7%	21	-18.6%
MYCAMINE	26	19.0%	28	15.8%	26	-1.3%	26	7.6%
Ambisome	27	-1.2%	29	-0.1%	30	-0.7%	30	29.6%
CRESEMBA	37	27.7%	35	25.5%	44	38.7%	39	29.3%
Scan	185	1.7%	179	4.6%	172	7.6%	158	-10.8%
Tarceva	15	-54.0%	5	-83.9%	6	-70.9%	4	-67.1%

(3) Established Market

Unit: M€

	FY19							
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue	613	3.8%	595	6.0%	592	-3.8%	650	14.4%
XTANDI	272	20.6%	272	22.2%	275	13.0%	302	28.6%
XOSPATA	-	-	-	-	1	-	6	-
BETMIGA	55	15.4%	58	23.1%	60	12.8%	61	22.4%
Vesicare	49	-18.3%	22	-59.8%	18	-68.7%	19	-66.4%
Prograf	143	-5.3%	140	1.1%	143	-7.5%	166	22.3%
Omnic	17	-2.2%	17	-2.0%	19	1.8%	18	6.3%
MYCAMINE	15	-11.2%	15	-0.7%	13	-11.8%	13	-0.9%
Eligard	25	-8.3%	23	-6.1%	26	-5.7%	24	5.7%

- Established Market: Europe, Canada, Australia

(4) Greater China

Unit: B¥

	FY19							
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue	14.7	7.4%	14.7	-5.9%	14.9	-5.1%	16.0	-7.8%
XTANDI	0.5	24.1%	0.5	-7.0%	0.7	23.5%	1.5	128.6%
BETMIGA	0.4	52.0%	0.3	2.2%	0.3	-12.7%	0.4	7.5%
Vesicare	0.5	14.6%	0.5	0.7%	0.5	-1.6%	0.4	-16.4%
Prograf	7.7	13.2%	7.8	-1.8%	7.7	-1.4%	9.0	2.3%
Harnal	3.3	3.0%	3.5	-5.6%	3.3	-19.1%	2.9	-29.8%
MYCAMINE	0.9	10.9%	0.8	-15.8%	1.3	64.0%	0.8	-23.1%
Eligard	0.1	21.1%	0.1	20.8%	0.1	18.7%	0.1	28.3%
Feburic	0.6	-2.4%	0.7	5.2%	0.6	2.5%	0.6	-1.0%

- Greater China: China, Hong Kong, Taiwan

(5) International

Unit: B¥

	FY19							
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Revenue	34.2	6.6%	29.1	-6.2%	39.5	25.6%	32.0	13.8%
XTANDI	5.7	58.7%	4.8	58.3%	6.8	57.2%	4.8	23.0%
BETMIGA	2.1	29.2%	2.0	25.5%	2.2	8.2%	2.1	11.6%
Vesicare	1.1	-6.6%	1.1	-7.6%	1.1	5.2%	0.9	-23.8%
Prograf	9.6	-1.0%	6.8	-5.5%	9.2	50.1%	6.1	-18.1%
Harnal	4.3	-4.8%	4.7	-2.1%	4.4	-4.0%	3.5	-14.6%
MYCAMINE	1.4	-7.9%	1.2	-5.0%	1.5	33.4%	1.3	36.5%

- International: Russia, Latin America, Middle East, Africa, South East Asia, South Asia, Korea, Export sales, etc.

R&D Pipeline

The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China. As of May 13, 2020

Underlined items indicate changes from the previous announcement on Jan 31, 2020.

Key post-POC projects and projects to maximize their VALUE (1/2)

Therapeutic Area	Generic Name Code No. (Brand Name)	Modality / Technology	Classification	Target Disease	Phase *	Licensor **	Remarks
Oncology	**enzalutamide** **MDV3100** **(XTANDI®)**	Small molecule	Androgen receptor inhibitor	Non-metastatic castration-resistant prostate cancer	China Filed (Oct 2019)	Pfizer	
				Metastatic castration-sensitive prostate cancer	Europe Filed (Jul 2019) Japan Filed (Jul 2019) China P-III		
				Non-metastatic castration-sensitive prostate cancer	P-III		
	gilteritinib **ASP2215** **(XOSPATA®)**	Small molecule	FLT3 inhibitor	Relapsed or refractory acute myeloid leukemia	China Filed (Mar 2020)	In-house	
				Post-chemotherapy maintenance acute myeloid leukemia	P-III		
				Post-hematopoietic stem cell transplant maintenance acute myeloid leukemia	P-III		
				Newly diagnosed acute myeloid leukemia with low intensity induction of chemotherapy	P-III		
				Newly diagnosed acute myeloid leukemia with high intensity induction of chemotherapy	P-III		
				Acute myeloid leukemia in pediatric patients	P-I		
	enfortumab vedotin **ASG-22ME** **(PADCEV®)**	Antibody-drug conjugate (ADC)	Nectin-4 targeted ADC	Metastatic urothelial cancer, PD-1/PD-L1 inhibitor and platinum-containing chemotherapy pretreated	P-III	In-house [Co-development with Seattle Genetics]	
				Metastatic urothelial cancer, previously untreated (first line; combo with pembrolizumab)	P-III		
				Metastatic urothelial cancer, PD-1/PD-L1 inhibitor pretreated	P-II		
				Other solid tumors	P-II		
	zolbetuximab **IMAB362**	Antibody	Anti-Claudin 18.2 monoclonal antibody	Gastric and gastroesophageal junction adenocarcinoma	P-III	In-house (Ganymed)	
				Pancreatic adenocarcinoma	P-II		

Key post-POC projects and projects to maximize their VALUE (2/2)

Therapeutic Area	Generic Name Code No. (Brand Name)	Modality / Technology	Classification	Target Disease	Phase *	Licensor **	Remarks
Urology and Nephrology	**roxadustat ASP1517/FG-4592**	Small molecule	HIF-PH inhibitor	Anemia associated with chronic kidney disease in patients on dialysis	Europe P-III	FibroGen	Astellas has rights in Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa.
				Anemia associated with chronic kidney disease in patients not on dialysis	Japan Filed (Jan 2020) Europe P-III		
				Chemotherapy-induced anemia	P-II		
Others	**fezolinetant ESN364**	Small molecule	NK3 receptor antagonist	Menopause-related vasomotor symptoms	P-III	In-house (Ogeda)	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.
** Compounds with "In-house" in this column include ones discovered by collaborative research.

Updates from the previous announcement (Jan 2020):
enzalutamide (MDV3100): Removed the description of the approval in China for metastatic castration-resistant prostate cancer in Nov 2019 and in US for metastatic castration-sensitive prostate cancer in Dec 2019.
enfortumab vedotin (ASG-22ME): Removed the description of the approval in US for locally advanced or metastatic urothelial cancer in patients who have received prior treatment with a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy in Dec 2019.
gilteritinib (ASP2215): Filed in China for relapsed or refractory acute myeloid leukemia with a FLT3 mutation in Mar 2020. Entered into Phase 1 for acute myeloid leukemia in pediatric patients.

Projects with Focus Area approach (1/2)

Target (Biology)	Generic Name Code No. (Brand Name)	Modality / Technology	Therapeutic Area	Classification	Target Disease	Phase *	Licensor **	Remarks
Immuno-oncology	**ASP8374/PTZ-201**	Antibody	Oncology	Anti-TIGIT antibody	Cancer	P-I	In-house (Potenza Therapeutics)	
	ASP1948/PTZ-329	Antibody	Oncology	Anti-NRP1 antibody	Cancer	P-I	In-house (Potenza Therapeutics)	
	ASP1951/PTZ-522	Antibody	Oncology	GITR agonistic antibody	Cancer	P-I	In-house (Potenza Therapeutics)	
	ASP9801	Oncolytic virus	Oncology	Oncolytic virus carrying IL-7 and IL-12	Cancer	P-I	Tottori University [Discovered through collaborative research]	
	ASP7517	Cell therapy (artificial adjuvant vector cells)	Oncology	WT1 loaded artificial adjuvant vector cell	Cancer	P-I	RIKEN [Discovered through collaborative research]	
Regeneration	**ASP7317**	Cell therapy	Ophthalmology	Retinal pigment epithelium cells	Dry age-related macular degeneration, Stargardt's disease	P-II	In-house (Astellas Institute for Regenerative Medicine)	
	FX-322	Small molecule	Otology	Inner ear progenitor cell activator (combination of GSK-3 inhibitor and HDAC inhibitor)	Sensorineural hearing loss	P-II	Frequency Therapeutics	Astellas has rights in Ex-US markets
	ASP0598	Recombinant protein	Otology	Recombinant human heparin-binding epidermal growth factor-like growth factor	Chronic tympanic membrane perforation	P-I	Auration Biotech	
Antigen-specific immuno-modulation (ASIM)	**ASP0892**	Next generation vaccine (LAMP-vax technology)	Immunology		Peanut allergy	P-I	Immunomic Therapeutics	
	ASP2390	New generation vaccine (LAMP-vax technology)	Immunology		House dust mite-induced allergic rhinitis	P-I	Immunomic Therapeutics [Discovered through collaborative research]	

Projects with Focus Area approach (2/2)

Target (Biology)	Generic Name Code No. (Brand Name)	Modality / Technology	Therapeutic Area	Classification	Target Disease	Phase *	Licensor **	Remarks
Mitochondria	**ASP1128/MA-0217**	Small molecule	Nephrology	PPARδ modulator	Acute kidney injury	P-II	In-house (Mitobridge)	
	ASP0367/MA-0211	Small molecule	Muscle disease		Duchenne muscular dystrophy	P-I	In-house (Mitobridge)	
Genetic regulation	**resamirigene bilparvovec AT132**	Gene therapy (AAV-based gene therapy)	Muscle disease	MTM1 gene replacement to express myotubularin	X-linked myotubular myopathy	P-II	In-house (Audentes)	
	AT845	Gene therapy (AAV-based gene therapy)	Muscle disease	GAA gene replacement to express GAA enzyme	Pompe disease	P-I	In-house (Audentes)	
Others	**ASP3772**	Next generation vaccine (MAPS technology)	Infectious disease	Pneumococcal vaccine based on a multiple antigen-presenting system (MAPS) platform	Prevention of pneumococcal disease	P-II	Affinivax	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.
** Compounds with "In-house" in this column include ones discovered by collaborative research.

Updates from the previous announcement (Jan 2020):
AT845: Entered into Phase 1 for Pompe disease.
reldesemtiv (CK-2127107): Discontinued the development for spinal muscular atrophy and amyotrophic lateral sclerosis in Phase 2 due to strategic prioritization.

Others

Therapeutic Area	Generic Name Code No. (Brand Name)	Modality / Technology	Classification	Target Disease	Phase *	Licensor **	Remarks
Oncology	**ASP1650**	Antibody	Anti-Claudin 6 monoclonal antibody	Testicular cancer	P-II	In-house (Ganymed)	
	ASP1235/AGS62P1	Antibody-drug conjugate (ADC)		Acute myeloid leukemia	P-I	In-house [ADC technology, EuCODE license from Ambrx]	
Urology and Nephrology	**solifenacin YM905**	Small molecule	Muscarine M_3 receptor antagonist	Neurogenic detrusor overactivity in pediatric patients	US Filed (Feb 2017)	In-house	
	mirabegron YM178	Small molecule	β_3 receptor agonist	Overactive bladder and neurogenic detrusor overactivity in pediatric patients	P-III	In-house	
	ASP8302	Small molecule	Muscarine M_3 receptor positive allosteric modulator	Underactive bladder	P-II	In-house	
Immunology	**peficitinib ASP015K**	Small molecule	JAK inhibitor	Rheumatoid arthritis	China P-III	In-house	
	bleselumab ASKP1240	Antibody	Anti-CD40 monoclonal antibody	Recurrence of focal segmental glomerulosclerosis in de novo kidney transplant recipients	P-II	Kyowa Kirin	
	ASP1617	Small molecule		Systemic lupus erythematosus	P-I	In-house	
Others	**fidaxomicin**	Small molecule	Macrocyclic antibiotic	*Clostridium difficile* infection in pediatric patients	Europe Approved (Feb 2020)	Merck	
	isavuconazole	Small molecule	Azole antifungal	Invasive aspergillosis and mucormycosis in pediatric patients	US P-II	Basilea	
	ASP8062	Small molecule	$GABA_B$ receptor positive allosteric modulator	Substance use disorders	P-I	In-house	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.
** Compounds with "In-house" in this column include ones discovered by collaborative research.

Update from the previous announcement (Jan 2020):
micafungin: Removed the description of the approval in US for invasive candidiasis in neonates and young infants less than 120 days of life in Dec 2019.
fidaxomicin: Approved in EU for c*lostridium difficile* infection in pediatric patients in Feb 2020.
ASP0819: Discontinued the development for fibromyalgia in Phase 2 due to strategic prioritization.
ASP4345: Discontinued the development for cognitive impairment associated with schizophrenia because Phase 2 study did not meet its primary endpoint.

Rx+™ Program

As of May 13, 2020

Underlined item indicates changes from the previous announcement on Jan. 31 2020

Sphere (Business area)	Project	Concept	Status	Partner	Remarks
Chronic disease progression prevention	Smartphone application	Offer smartphone application to support exercise using wearable device to people who needs regular exercise	Implementing medical and health research	BANDAI NAMCO Entertainment	
	BlueStar	Digital therapeutics for adults with diabetes	Preparing for product development	Welldoc	
Patient outcome maximization	ASP5354	Precision surgery-guide enabling identification of ureter in hysterectomy and colorectal surgery, etc.	P-Ⅱ		

Update from the previous announcement (Jan 2020):

Smartphone application: Enter into agreement with BANDAI NAMCO Entertainment to co-develop and co-commercialize smartphone exercise support application